Literature DB >> 35199205

Myeloid cell thrombus and fetal vascular malperfusion in placentas with transient abnormal myelopoiesis.

Kayo Tomimori1, Yuki Kodama1, Hiroyuki Tanaka2, Atushi Yamashita2, Toshihiro Gi2, Yujiro Asada2, Koutarou Doi1, Shinji Katsuragi1, Yuichiro Sato3.   

Abstract

Transient abnormal myelopoiesis (TAM), also known as transient myeloproliferative disorder or transient leukemia, is a self-regressing neoplasia that afflicts infants with trisomy 21. A recent review article documented "myeloid cell thrombus (MCT)" and "fetal vascular malperfusion (FVM)" in placentas with TAM, although the characteristic TAM placental findings have not been clarified. Here, we compared the clinical and pathological placental findings between trisomy 21 patients with or without TAM. In 13 cases of trisomy 21, we identified six placentas with TAM and seven placentas without TAM. The six placentas with TAM included two stillborn cases. Microscopically, MCT was noted in all the cases, and a high incidence of FVM (50%) was observed in TAM cases. Immunohistochemically, MCT was found to be a platelet-rich thrombus. The placentas were grouped according to the presence or absence of TAM and subsequently compared. Clinically, the incidences of abnormal fetal heart rate pattern and fetal or neonatal death were significantly higher in TAM cases. Pathologically, placenta in TAM cases weighted more than those in cases without TAM, and the incidence of MCT was significantly higher in placentas with TAM. Moreover, the incidence of FVM was higher in placentas with TAM, but this difference was not statistically significant. We propose that MCT is a diagnostic feature of placentas with TAM and may be associated with poor fetal outcomes.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Fetal vascular malperfusion; Myeloid cell thrombosis; Pathology; Placenta; Transient abnormal myelopoiesis

Mesh:

Year:  2022        PMID: 35199205     DOI: 10.1007/s00428-022-03289-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

1.  Histomorphological features of chorionic villi at 10-14 weeks of gestation in trisomic and chromosomally normal pregnancies.

Authors:  L Roberts; N J Sebire; D Fowler; K H Nicolaides
Journal:  Placenta       Date:  2000-09       Impact factor: 3.481

2.  Placental pathology in maternal and neonatal myeloproliferative disorders.

Authors:  S E Lentz; C C Coulson; C D Gocke; A P Fantaskey
Journal:  Obstet Gynecol       Date:  1998-05       Impact factor: 7.661

Review 3.  Trisomy 21-associated transient abnormal myelopoiesis involving the maternal space of the placenta: a case report and literature review.

Authors:  Qian Dai; Vishnu V B Reddy; John K Choi; Ona M Faye-Petersen
Journal:  Pediatr Dev Pathol       Date:  2014-06-27

4.  Transient abnormal myelopoiesis/acute megakaryoblastic leukemia diagnosed in the placenta of a stillborn Down syndrome fetus with targeted next-generation sequencing.

Authors:  B Federmann; A Fasan; K O Kagan; S Haen; F Fend
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

5.  Transient myeloproliferative disease of the newborn: case report with placental, cytogenetic, and flow cytometric findings.

Authors:  M W de Tar; W Dittman; J Gilbert
Journal:  Hum Pathol       Date:  2000-03       Impact factor: 3.466

6.  Extensive placental choriovascular infiltration by maturing myeloid cells in down syndrome-associated transient abnormal myelopoiesis.

Authors:  Sanjita Ravishankar; Laurie Hoffman; Terakeith Lertsburapa; Jennifer Welch; Diana Treaba; Monique E De Paepe
Journal:  Pediatr Dev Pathol       Date:  2015-01-14

7.  Trisomy 21 placentas: histopathological and immunohistochemical findings using proliferating cell nuclear antigen.

Authors:  F Qureshi; S M Jacques; M P Johnson; R F Hume; R L Kramer; Y Yaron; M I Evans
Journal:  Fetal Diagn Ther       Date:  1997 Jul-Aug       Impact factor: 2.587

8.  Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.

Authors:  Brandie Heald; Joanne M Hilden; Kevin Zbuk; Alice Norton; Paresh Vyas; Karl S Theil; Charis Eng
Journal:  Nat Clin Pract Oncol       Date:  2007-07

Review 9.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

Authors:  Sébastien Malinge; Shai Izraeli; John D Crispino
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

10.  Congenital GATA1-mutated myeloproliferative disorder in trisomy 21 complicated by placental fetal thrombotic vasculopathy.

Authors:  Tracy J Z Loh; Derrick W Q Lian; Prasad Iyer; Joyce C M Lam; Chik H Kuick; Aye C L Aung; Kenneth Tou En Chang
Journal:  Hum Pathol       Date:  2014-08-16       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.